scispace - formally typeset
M

Markus Sack

Researcher at RWTH Aachen University

Publications -  75
Citations -  5070

Markus Sack is an academic researcher from RWTH Aachen University. The author has contributed to research in topics: Antibody & Fusion protein. The author has an hindex of 34, co-authored 73 publications receiving 4473 citations. Previous affiliations of Markus Sack include Fraunhofer Society.

Papers
More filters
Journal ArticleDOI

COVID-19 vaccine development and a potential nanomaterial path forward.

TL;DR: Current approaches to COVID-19 vaccine development are highlighted, highlighting the role of nanotechnology, manufacturing and distribution and a successful vaccine platform must enable rapid discovery, scalable manufacturing and global distribution.
Journal ArticleDOI

Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium

TL;DR: The results suggest that heterophilic interactions with PF4 require structural motifs important in RANTES oligomerization and amplify RantES-triggered effects on monocyte adhesion, which may have implications for the modulation of inflammatory recruitment by platelet-derived chemokines.
Journal ArticleDOI

Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies.

TL;DR: The stable expression of a medically important antibody in the staple cereal crops rice and wheat is described, establishing that molecular pharming in cereals can be a viable production system for such high-value pharmaceutical macromolecules.
Journal ArticleDOI

Transient expression of a tumor-specific single-chain fragment and a chimeric antibody in tobacco leaves.

TL;DR: In this paper, a recombinant single-chain Fv antibody (scFvT84.66) and a full-size mouse/human chimeric antibody derived from the parental murine mAb T 84.66 specific for the human carcinoembryonic antigen were engineered into a plant expression vector.
Journal ArticleDOI

Plantibodies: applications, advantages and bottlenecks.

TL;DR: Recent research developments focus on the fine-tuning of expression systems and the detailed characterisation of recombinant products, including the implications of plant-specific glycosylation.